StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a note issued to investors on Tuesday. The firm set a "hold" rating on the biotechnology company's stock.
Separately, Northland Securities downgraded shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a report on Friday, January 6th.
Get
Nabriva Therapeutics alerts:
Nabriva Therapeutics Stock Up 5.7 %
NASDAQ:NBRV opened at $1.49 on Tuesday. The firm has a market cap of $45.65 million, a P/E ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $14.19. The firm has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $3.74.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share for the quarter, missing analysts' consensus estimates of ($4.03) by ($0.18). The firm had revenue of $9.15 million for the quarter, compared to the consensus estimate of $10.68 million. Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. Analysts predict that Nabriva Therapeutics will post -17.37 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after buying an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is currently owned by institutional investors and hedge funds.
Nabriva Therapeutics Company Profile
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Further Reading
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Don't Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a note issued to investors on Tuesday. The firm set a "hold" rating on the biotechnology company's stock.
證券新聞網開始對股票的報導 納布里瓦治療學 (NASDAQ: NBRV — 獲得評分) 在星期二發給投資者的票據中。該公司對生物技術公司的股票設定了「持有」評級。
Separately, Northland Securities downgraded shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a report on Friday, January 6th.
另外，北國證券在 1 月 6 日（星期五）的報告中，將 Nabriva 治療學的股票從「跑贏大市」評級降級為「表現不佳」評級。
Get
Nabriva Therapeutics
alerts:
Nabriva Therapeutics Stock Up 5.7 %
NASDAQ:NBRV opened at $1.49 on Tuesday. The firm has a market cap of $45.65 million, a P/E ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $14.19. The firm has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $3.74.
納斯達克：NBRV 星期二以 1.49 美元的價格開盤。該公司的市值為 4,565 萬美元，市盈率為 -0.08，貝塔值為 1.67。該公司的債務與權益比率為 0.02，快速比率為 1.40，流動比率為 2.20。納布里瓦治療學的五十二周低點為 1.22 美元，五十二周高點為 14.19 美元。該公司擁有 50 天的簡單移動平均線 1.97 美元，而兩百天的簡單移動平均線為 3.74 美元。
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share for the quarter, missing analysts' consensus estimates of ($4.03) by ($0.18). The firm had revenue of $9.15 million for the quarter, compared to the consensus estimate of $10.68 million. Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. Analysts predict that Nabriva Therapeutics will post -17.37 earnings per share for the current fiscal year.
納布里瓦治療學（NASDAQ：NBRV-獲取評級）最近一次發布了其季度收益數據，週四，11 月 10 日。該生物技術公司報告了本季度每股收益（4.21 美元），缺失分析師的共識估計（4.03 美元）通過（0.18 美元）報告。該公司本季度的收入為 9.15 萬美元，而共識估計為 1068 萬美元。納布里瓦治療學的負淨利潤率為 133.25％，負資產回報率為 120.02％。分析師預測，納布里瓦治療學將發布當前財政年度的每股盈利 -17.37。
Hedge Funds Weigh In On Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after buying an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is currently owned by institutional investors and hedge funds.
一名機構投資者最近提出了在 Nabriva 治療學股票的地位。根據該公司最近與證券交易委員會的披露，文藝復興技術有限責任公司（NASDAQ：NBRV-獲得評級）在第二季度將其在納布里瓦治療有限公司的持有量增加了 102.1％。該基金在本季度額外購買 402,144 股股票後，擁有該生物科技公司股票的 795,938 股。在最近的報告期結束時，文藝復興技術有限責任公司擁有納布里瓦治療學的 0.13％，價值 145,000 美元。0.23％ 的股票目前由機構投資者和對沖基金擁有。
Nabriva Therapeutics Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Theraptics Plc 是一家生物製藥公司，致力於治療嚴重感染的新型抗感染藥物的研究，開發和商業化。其產品管線包括利福霉素、聯盟和 BC-7013。該公司成立於 2005 年 10 月，總部位於愛爾蘭都柏林。
Further Reading
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Don't Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- 獲取有關納布里瓦治療學（NBRV）的研究報告的免費副本
- 不要錯過這些 2 上週爆發的中型股技術人員
- 澳門是永利渡假村沉船嗎？
- 為什麼華納兄弟發現是標普最熱門的股票
- Pinterest 是 2023 年值得關注的社交商務平台
- 沃爾格林靴子聯盟收益小姐對投資者有好處嗎？
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收納布里瓦治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Nabriva 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
